NZ522264A - Retroviral vectors comprising an enhanced 3' transcription termination structure - Google Patents
Retroviral vectors comprising an enhanced 3' transcription termination structureInfo
- Publication number
- NZ522264A NZ522264A NZ522264A NZ52226401A NZ522264A NZ 522264 A NZ522264 A NZ 522264A NZ 522264 A NZ522264 A NZ 522264A NZ 52226401 A NZ52226401 A NZ 52226401A NZ 522264 A NZ522264 A NZ 522264A
- Authority
- NZ
- New Zealand
- Prior art keywords
- sequence
- sequences
- retroviral vector
- ltr
- heterologous
- Prior art date
Links
- 239000013598 vector Substances 0.000 title claims abstract description 207
- 230000001177 retroviral effect Effects 0.000 title claims abstract description 108
- 230000005030 transcription termination Effects 0.000 title description 36
- 230000008488 polyadenylation Effects 0.000 claims abstract description 78
- 238000011144 upstream manufacturing Methods 0.000 claims abstract description 34
- 239000003623 enhancer Substances 0.000 claims abstract description 17
- 210000004027 cell Anatomy 0.000 claims description 73
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims description 29
- 239000002245 particle Substances 0.000 claims description 27
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 claims description 22
- 108091026890 Coding region Proteins 0.000 claims description 17
- 230000037430 deletion Effects 0.000 claims description 16
- 238000012217 deletion Methods 0.000 claims description 16
- 229920001184 polypeptide Polymers 0.000 claims description 15
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 15
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 15
- 230000003612 virological effect Effects 0.000 claims description 15
- 241000700735 Ground squirrel hepatitis virus Species 0.000 claims description 9
- 241000713730 Equine infectious anemia virus Species 0.000 claims description 8
- 208000015181 infectious disease Diseases 0.000 claims description 7
- 230000002458 infectious effect Effects 0.000 claims description 7
- 210000004962 mammalian cell Anatomy 0.000 claims description 7
- 241000701489 Cauliflower mosaic virus Species 0.000 claims description 5
- 210000005260 human cell Anatomy 0.000 claims description 5
- 108010052219 lamin B2 Proteins 0.000 claims description 5
- 102000004381 Complement C2 Human genes 0.000 claims description 3
- 108090000955 Complement C2 Proteins 0.000 claims description 3
- 102100026519 Lamin-B2 Human genes 0.000 claims description 3
- 230000001566 pro-viral effect Effects 0.000 claims description 3
- 230000001225 therapeutic effect Effects 0.000 claims description 3
- 239000003550 marker Substances 0.000 claims description 2
- 241001465754 Metazoa Species 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 description 38
- 108090000623 proteins and genes Proteins 0.000 description 38
- 125000003729 nucleotide group Chemical group 0.000 description 37
- 230000014509 gene expression Effects 0.000 description 25
- 238000004806 packaging method and process Methods 0.000 description 24
- 241001430294 unidentified retrovirus Species 0.000 description 22
- 230000000694 effects Effects 0.000 description 20
- 108020004999 messenger RNA Proteins 0.000 description 14
- 230000010076 replication Effects 0.000 description 12
- 230000035897 transcription Effects 0.000 description 12
- 238000013518 transcription Methods 0.000 description 12
- 102100034349 Integrase Human genes 0.000 description 11
- 241000700605 Viruses Species 0.000 description 11
- 230000010354 integration Effects 0.000 description 11
- 238000004519 manufacturing process Methods 0.000 description 11
- 238000003556 assay Methods 0.000 description 10
- 238000003776 cleavage reaction Methods 0.000 description 9
- 102000040430 polynucleotide Human genes 0.000 description 9
- 108091033319 polynucleotide Proteins 0.000 description 9
- 239000002157 polynucleotide Substances 0.000 description 9
- 230000007017 scission Effects 0.000 description 9
- 238000013459 approach Methods 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- 230000002103 transcriptional effect Effects 0.000 description 8
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 7
- 230000002950 deficient Effects 0.000 description 7
- 241000725303 Human immunodeficiency virus Species 0.000 description 6
- 108700005077 Viral Genes Proteins 0.000 description 6
- 238000003780 insertion Methods 0.000 description 6
- 230000037431 insertion Effects 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 102000039446 nucleic acids Human genes 0.000 description 6
- 108020004707 nucleic acids Proteins 0.000 description 6
- 150000007523 nucleic acids Chemical class 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 5
- 108010061833 Integrases Proteins 0.000 description 5
- 108091034057 RNA (poly(A)) Proteins 0.000 description 5
- 241000711975 Vesicular stomatitis virus Species 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 230000000717 retained effect Effects 0.000 description 5
- 101710091045 Envelope protein Proteins 0.000 description 4
- 241000713666 Lentivirus Species 0.000 description 4
- 101710188315 Protein X Proteins 0.000 description 4
- 108010067390 Viral Proteins Proteins 0.000 description 4
- 231100000599 cytotoxic agent Toxicity 0.000 description 4
- 239000002619 cytotoxin Substances 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 238000010348 incorporation Methods 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 230000006798 recombination Effects 0.000 description 4
- 238000005215 recombination Methods 0.000 description 4
- 238000010839 reverse transcription Methods 0.000 description 4
- 241000701161 unidentified adenovirus Species 0.000 description 4
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 3
- 241000713800 Feline immunodeficiency virus Species 0.000 description 3
- 108091006027 G proteins Proteins 0.000 description 3
- 102000030782 GTP binding Human genes 0.000 description 3
- 108091000058 GTP-Binding Proteins 0.000 description 3
- 241000713869 Moloney murine leukemia virus Species 0.000 description 3
- 241000714177 Murine leukemia virus Species 0.000 description 3
- 108091036407 Polyadenylation Proteins 0.000 description 3
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 3
- 108700008625 Reporter Genes Proteins 0.000 description 3
- 102000006382 Ribonucleases Human genes 0.000 description 3
- 108010083644 Ribonucleases Proteins 0.000 description 3
- 241000714474 Rous sarcoma virus Species 0.000 description 3
- 108091036066 Three prime untranslated region Proteins 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 108010027225 gag-pol Fusion Proteins Proteins 0.000 description 3
- 238000001415 gene therapy Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108020005544 Antisense RNA Proteins 0.000 description 2
- 241000713826 Avian leukosis virus Species 0.000 description 2
- 101100042630 Caenorhabditis elegans sin-3 gene Proteins 0.000 description 2
- 108090000994 Catalytic RNA Proteins 0.000 description 2
- 102000053642 Catalytic RNA Human genes 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 108090000331 Firefly luciferases Proteins 0.000 description 2
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 2
- 101000993321 Homo sapiens Complement C2 Proteins 0.000 description 2
- 102100034353 Integrase Human genes 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- 241000713883 Myeloproliferative sarcoma virus Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 108010052090 Renilla Luciferases Proteins 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 241000713311 Simian immunodeficiency virus Species 0.000 description 2
- 241000283925 Spermophilus Species 0.000 description 2
- 241000713896 Spleen necrosis virus Species 0.000 description 2
- 241000713325 Visna/maedi virus Species 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 108010078428 env Gene Products Proteins 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 238000001476 gene delivery Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108091092562 ribozyme Proteins 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000002463 transducing effect Effects 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 102100025230 2-amino-3-ketobutyrate coenzyme A ligase, mitochondrial Human genes 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 108010087522 Aeromonas hydrophilia lipase-acyltransferase Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000003508 Botulism Diseases 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 108091029865 Exogenous DNA Proteins 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 229940096437 Protein S Drugs 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- 102000009572 RNA Polymerase II Human genes 0.000 description 1
- 108010009460 RNA Polymerase II Proteins 0.000 description 1
- 108020004518 RNA Probes Proteins 0.000 description 1
- 239000003391 RNA probe Substances 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 102000039471 Small Nuclear RNA Human genes 0.000 description 1
- 108020004688 Small Nuclear RNA Proteins 0.000 description 1
- 101710198474 Spike protein Proteins 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108700029229 Transcriptional Regulatory Elements Proteins 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 208000004668 avian leukosis Diseases 0.000 description 1
- 208000005266 avian sarcoma Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960000182 blood factors Drugs 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 108700004025 env Genes Proteins 0.000 description 1
- 101150030339 env gene Proteins 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108700004026 gag Genes Proteins 0.000 description 1
- 101150098622 gag gene Proteins 0.000 description 1
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 1
- 229960002963 ganciclovir Drugs 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000000633 nuclear envelope Anatomy 0.000 description 1
- 230000030147 nuclear export Effects 0.000 description 1
- 230000012223 nuclear import Effects 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 230000006548 oncogenic transformation Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 108010089520 pol Gene Products Proteins 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 210000000605 viral structure Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/30—Vector systems having a special element relevant for transcription being an enhancer not forming part of the promoter region
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/36—Vector systems having a special element relevant for transcription being a transcription termination element
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/60—Vector systems having a special element relevant for transcription from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Orthopedics, Nursing, And Contraception (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20388400P | 2000-05-12 | 2000-05-12 | |
| PCT/IB2001/000826 WO2001085974A2 (en) | 2000-05-12 | 2001-05-14 | Retroviral vectors comprising an enhanced 3' transcription termination structure |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ522264A true NZ522264A (en) | 2004-08-27 |
Family
ID=22755701
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ522264A NZ522264A (en) | 2000-05-12 | 2001-05-14 | Retroviral vectors comprising an enhanced 3' transcription termination structure |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US6620595B2 (enExample) |
| EP (1) | EP1283895A2 (enExample) |
| JP (1) | JP4708661B2 (enExample) |
| AU (1) | AU2001258668A1 (enExample) |
| CA (1) | CA2408786C (enExample) |
| IL (2) | IL152527A0 (enExample) |
| NZ (1) | NZ522264A (enExample) |
| WO (1) | WO2001085974A2 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1412493B1 (en) | 2001-08-02 | 2011-10-05 | Institut Clayton De La Recherche | Methods and compositions relating to improved lentiviral vector production systems |
| EP1794308B1 (en) * | 2004-09-29 | 2013-08-28 | Pioneer-Hi-Bred International, Inc. | Corn event das-59122-7 and methods for detection thereof |
| EP2598636A4 (en) * | 2010-07-26 | 2014-03-05 | Adv Biolog Inc | VECTORS AND METHODS FOR EXPRESSION OF RECOMBINANT PROTEINS |
| CN102533863A (zh) * | 2011-11-25 | 2012-07-04 | 上海市儿童医院 | 一种低通读率慢病毒载体及方法 |
| CN102443604B (zh) * | 2011-11-25 | 2014-12-31 | 上海市儿童医院 | 一种安全性慢病毒载体及其应用 |
| EP2970955B1 (en) | 2013-03-14 | 2018-11-14 | Translate Bio, Inc. | Methods for purification of messenger rna |
| GB202114532D0 (en) | 2021-10-12 | 2021-11-24 | Oxford Biomedica Ltd | Lentiviral Vectors |
-
2001
- 2001-05-14 US US09/855,159 patent/US6620595B2/en not_active Expired - Lifetime
- 2001-05-14 NZ NZ522264A patent/NZ522264A/en not_active IP Right Cessation
- 2001-05-14 IL IL15252701A patent/IL152527A0/xx unknown
- 2001-05-14 AU AU2001258668A patent/AU2001258668A1/en not_active Abandoned
- 2001-05-14 CA CA2408786A patent/CA2408786C/en not_active Expired - Fee Related
- 2001-05-14 EP EP01931987A patent/EP1283895A2/en not_active Withdrawn
- 2001-05-14 JP JP2001582562A patent/JP4708661B2/ja not_active Expired - Fee Related
- 2001-05-14 WO PCT/IB2001/000826 patent/WO2001085974A2/en not_active Ceased
-
2002
- 2002-10-28 IL IL152527A patent/IL152527A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| US20020042136A1 (en) | 2002-04-11 |
| JP4708661B2 (ja) | 2011-06-22 |
| US6620595B2 (en) | 2003-09-16 |
| AU2001258668A1 (en) | 2001-11-20 |
| EP1283895A2 (en) | 2003-02-19 |
| IL152527A (en) | 2009-06-15 |
| CA2408786A1 (en) | 2001-11-15 |
| IL152527A0 (en) | 2003-05-29 |
| WO2001085974A2 (en) | 2001-11-15 |
| JP2003532426A (ja) | 2003-11-05 |
| WO2001085974A3 (en) | 2002-07-04 |
| CA2408786C (en) | 2012-05-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7056699B2 (en) | Lentiviral LTR-deleted vector | |
| Baum et al. | Retrovirus vectors: toward the plentivirus? | |
| JP4640742B2 (ja) | 高力価で安全な組換えレンチウイルスベクター作成の方法及び手段 | |
| US8034620B2 (en) | Lentiviral packaging cells and uses therefor | |
| KR20160122125A (ko) | 바이러스 벡터 생산 시스템 | |
| JP2007054069A (ja) | 自己不活性化レトロウイルスベクター | |
| US20060019393A1 (en) | Minimal lentiviral vector system | |
| CA2408786C (en) | Retroviral vectors comprising an enhanced 3' transcription termination structure | |
| US9840720B2 (en) | Materials and methods relating to packaging cell lines | |
| Fuller et al. | Helper plasmids for production of HIV-1-derived vectors | |
| Barker et al. | Vectors derived from the human immunodeficiency virus, HIV-1 | |
| Schambach et al. | Retroviral vectors for cell and gene therapy | |
| US20230151388A1 (en) | Modified vectors for production of retrovirus | |
| EP1183383B1 (en) | Siv-based packaging-deficient vectors | |
| US20060134137A1 (en) | Transduction vector based on modified HIV-2 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 7 YEARS UNTIL 14 MAY 2021 BY CPA GLOBAL Effective date: 20140327 |
|
| EXPY | Patent expired |